^
Association details:
| Biomarker: | FLT1 amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identifying predictive biomarkers of apatinib in third-line treatment of advanced colorectal cancer through comprehensive genomic profiling
Published date:
11/18/2022
Excerpt:
We retrospectively recruited 19 CRC patients receiving apatinib as third-line treatment….Patients harboring FLT1 amplifications (n = 3) showed significantly worse PFS than wild-type patients. Our study described molecular profiles in CRC patients receiving apatinib treatment and identified FLT1 amplification as a potential predictive biomarker for poor efficacy of apatinib.
DOI:
10.1097/CAD.0000000000001451
Source:
Title:
FLT1 amplification predicts poor response in metastatic colorectal cancer patients treated with apatinib as 3rd line treatment.
Published date:
05/28/2020
Excerpt:
19 mCRC patients, with a median age of 53, treated with apatinib as the third-line regimen....potential predictive biomerkers for apatinib and revealed that FLT1 amplification might be a potential predictive biomarker for poor efficacy in mCRC patients treated with apatinib. FLT1 encodes VEGFR1, which could compete with VEGFR2 for binding with VEGF, potentially explaining the inferior response to apatinib observed in pateints harboring FLT1 amplification.
DOI:
10.1200/JCO.2020.38.15_suppl.e16033
